Vor Biopharma raises $75M via private placement with TCGX for telitacicept development

Vor Biopharma Inc.

Gross proceeds of $75M from sale of 5.34M shares at $14.05/share to TCGX affiliates.
Closing expected March 30, 2026; no placement agent used.
Proceeds to advance Phase 3 trials for myasthenia gravis and primary Sjögren's disease.
TCGX managing partner expresses confidence in telitacicept's differentiated profile.
Registration rights agreement to file resale registration statement within 30 days.

item 1.01item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.